Patents by Inventor Bismarck CAMPOS

Bismarck CAMPOS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITION OF OLIG2 ACTIVITY
    Publication number: 20230271926
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: May 10, 2023
    Publication date: August 31, 2023
    Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. McHARDY, Francisco Xavier RUIZ, Ambrosio LOPEZ, Bismarck CAMPOS, Hua-Yu Leo WANG
  • Inhibition of Olig2 activity
    Patent number: 11691951
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Grant
    Filed: July 2, 2021
    Date of Patent: July 4, 2023
    Assignee: CURTANA PHARMACEUTICALS, INC.
    Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Stanton F. McHardy, Francisco Xavier Ruiz, Ambrosio Lopez, Bismarck Campos, Hua-Yu Leo Wang
  • Inhibition of Olig2 activity
    Patent number: 11685722
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: June 27, 2023
    Assignee: CURTANA PHARMACEUTICALS, INC.
    Inventors: Graham Beaton, Stanton F. McHardy, Ambrosio Lopez, Jr., Bismarck Campos, Hua-Yu Leo Wang
  • Inhibition of OLIG2 activity
    Patent number: 11242323
    Abstract: Described herein are urea compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: February 8, 2022
    Assignee: CURTANA PHARMACEUTICALS, INC.
    Inventors: Graham Beaton, Stanton F. McHardy, Ambrosio Lopez, Jr., Bismarck Campos, Hua-Yu Leo Wang
  • INHIBITION OF OLIG2 ACTIVITY
    Publication number: 20210347739
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: July 2, 2021
    Publication date: November 11, 2021
    Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. McHARDY, Francisco Xavier RUIZ, Ambrosio LOPEZ, Bismarck CAMPOS, Hua-Yu Leo WANG
  • INHIBITION OF OLIG2 ACTIVITY
    Publication number: 20210253535
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: April 19, 2021
    Publication date: August 19, 2021
    Inventors: Graham BEATON, Stanton F. McHARDY, Ambrosio LOPEZ, Jr., Bismarck CAMPOS, Hua-Yu Leo WANG
  • INHIBITION OF OLIG2 ACTIVITY
    Publication number: 20210114991
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: November 20, 2020
    Publication date: April 22, 2021
    Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. McHARDY, Francisco Xavier RUIZ, Ambrosio LOPEZ, Bismarck CAMPOS, Hua-Yu Leo WANG
  • INHIBITION OF OLIG2 ACTIVITY
    Publication number: 20200407329
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: February 28, 2019
    Publication date: December 31, 2020
    Inventors: Graham BEATON, Stanton F. McHARDY, Ambrosio LOPEZ, Jr., Bismarck CAMPOS, Hua-Yu Leo WANG
  • INHIBITION OF OLIG2 ACTIVITY
    Publication number: 20190389812
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 26, 2019
    Inventors: Graham BEATON, Stanton F. McHARDY, Ambrosio LOPEZ, JR., Bismarck CAMPOS, Hua-Yu Leo WANG
  • INHIBITION OF OLIG2 ACTIVITY
    Publication number: 20180244631
    Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.
    Type: Application
    Filed: February 26, 2016
    Publication date: August 30, 2018
    Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. MCHARDY, Francisco Xavier RUIZ, III, Ambrosio LOPEZ, Jr., Bismarck CAMPOS, Hua-Yu Leo WANG
  • Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitors
    Patent number: 9169220
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: October 27, 2015
    Assignee: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • Oximes For Treatment Of Peripheral And Central Nervous System Exposure to Acetyl Cholinesterase Inhibitors
    Publication number: 20150005328
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 1, 2015
    Inventors: Stanton F. MCHARDY, Richard M. CORBETT, Donald M. MAXWELL, Michael W. TIDWELL, Bismarck CAMPOS, Christopher J. BEMBEN
  • Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitors
    Patent number: 8772345
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Grant
    Filed: August 3, 2011
    Date of Patent: July 8, 2014
    Assignee: Southwest Research Institute
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • OXIMES FOR TREATMENT OF PERIPHERAL AND CENTRAL NERVOUS SYSTEM EXPOSURE TO ACETYL CHOLINESTERASE INHIBITORS
    Publication number: 20140066421
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Application
    Filed: May 17, 2012
    Publication date: March 6, 2014
    Applicant: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • Oximes for treatment of peripheral and central nervous system exposure to acetyl cholinesterase inhibitors
    Patent number: 8653108
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Grant
    Filed: May 17, 2012
    Date of Patent: February 18, 2014
    Assignee: Southwest Research Institute
    Inventors: Stanton F. McHardy, Richard M. Corbett, Donald M. Maxwell, Michael W. Tidwell, Bismarck Campos, Christopher J. Bemben
  • Oximes For Treatment Of Peripheral And Central Nervous System Exposure To Acetyl Cholinesterase Inhibitors
    Publication number: 20130035351
    Abstract: The present invention relates to non-charged oxime compounds which are acetyl cholinesterase (AChE) reactivators of inhibited AChE and which protect against organophosphate poisoning both peripherally and in the central nervous system. Also disclosed are pharmaceutical compositions and methods for preparing the reactivator compounds and associated intermediates.
    Type: Application
    Filed: August 3, 2011
    Publication date: February 7, 2013
    Applicant: SOUTHWEST RESEARCH INSTITUTE
    Inventors: Stanton F. MCHARDY, Richard M. CORBETT, Donald M. MAXWELL, Michael W. TIDWELL, Bismarck CAMPOS, Christopher J. BEMBEN